| Kris Tarlton, CRNA | |
|
3515 Broadway Ave, Great Bend, KS 67530-3633 | |
| (316) 685-6091 | |
| Not Available |
| Full Name | Kris Tarlton |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 27 Years |
| Location | 3515 Broadway Ave, Great Bend, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386863272 | NPI | - | NPPES |
| 145284 | Other | KS | BCBS |
| P00311025 | Other | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55473 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Ks Hlth System Great Bend Campus | Great bend, KS | Hospital |
| Hays Medical Center | Hays, KS | Hospital |
| Ellinwood District Hospital | Ellinwood, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hays Medical Center Inc | 1557279676 | 158 |
| Ukhs Great Bend Llc | 5597016378 | 66 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
| Entity Name | Central Kansas Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497723225 PECOS PAC ID: 8325940497 Enrollment ID: O20040128000846 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
| Entity Name | Hays Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770618258 PECOS PAC ID: 1557279676 Enrollment ID: O20040224000687 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
| Entity Name | New Wave Anesthesia Service Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811474760 PECOS PAC ID: 7719237494 Enrollment ID: O20180829003218 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
| Entity Name | Ukhs Great Bend Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962997197 PECOS PAC ID: 5597016378 Enrollment ID: O20180918000770 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kris Tarlton, CRNA 9313 E 34th St N Ste 100, Wichita, KS 67226-2638 Ph: (316) 685-6091 | Kris Tarlton, CRNA 3515 Broadway Ave, Great Bend, KS 67530-3633 Ph: (316) 685-6091 |
News Archive
A new multinational study shows that the most popular first-line treatment for hypertension is less effective and has more side effects than an alternative that's prescribed much less often.
Asia Pacific (APAC) is the fastest growing healthcare information technology (healthcare IT) market across the world. Within APAC, after Japan, Australia is the second largest market for health technology adoption.
Researchers have successfully treated age-related macular degeneration in mice after finding an unexpected link between the two main forms of the blinding eye disease, the leading cause of vision loss in people 60 and older.
48 healthy males participated in the experiment. Half received an oxytocin nose spray at the start of the experiment, the other half a placebo. The researchers then showed their test subjects photos of emotionally charged situations in the form of a crying child, a girl hugging her cat, and a grieving man. The test subjects were then invited to express the depth of feeling they experienced for the persons shown.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 7 days ago
Garrett T Rebel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 3515 Broadway Ave, Great Bend, KS 67530 Phone: 800-475-6236 | |
Mrs. Erin D Glassman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 514 Cleveland St, Great Bend, KS 67530 Phone: 620-792-9600 | |
Robert M Symes, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 3515 Broadway Ave, Great Bend, KS 67530 Phone: 620-792-2511 |